LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 106 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $63,450 | 0.0% | 45,000 | 0.0% | 0.05% | 0.0% |
Q2 2023 | $63,450 | -6.0% | 45,000 | 0.0% | 0.05% | +8.5% |
Q1 2023 | $67,500 | +28.2% | 45,000 | 0.0% | 0.05% | +80.8% |
Q4 2022 | $52,650 | +3.2% | 45,000 | 0.0% | 0.03% | +36.8% |
Q3 2022 | $51,000 | -28.2% | 45,000 | 0.0% | 0.02% | -58.7% |
Q2 2022 | $71,000 | +1.4% | 45,000 | 0.0% | 0.05% | +17.9% |
Q1 2022 | $70,000 | -36.4% | 45,000 | 0.0% | 0.04% | -35.0% |
Q4 2021 | $110,000 | -2.7% | 45,000 | 0.0% | 0.06% | -6.2% |
Q3 2021 | $113,000 | -11.7% | 45,000 | 0.0% | 0.06% | -8.6% |
Q2 2021 | $128,000 | +20.8% | 45,000 | 0.0% | 0.07% | +12.9% |
Q1 2021 | $106,000 | +34.2% | 45,000 | 0.0% | 0.06% | +59.0% |
Q4 2020 | $79,000 | +88.1% | 45,000 | 0.0% | 0.04% | +56.0% |
Q3 2020 | $42,000 | -31.1% | 45,000 | -35.7% | 0.02% | -50.0% |
Q2 2020 | $61,000 | +64.9% | 70,000 | +55.6% | 0.05% | +25.0% |
Q1 2020 | $37,000 | -7.5% | 45,000 | 0.0% | 0.04% | +14.3% |
Q4 2019 | $40,000 | -9.1% | 45,000 | 0.0% | 0.04% | -5.4% |
Q3 2019 | $44,000 | – | 45,000 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $39,477,000 | 3.01% |
Raffles Associates | 2,080,536 | $2,351,000 | 2.51% |
Defender Capital, LLC. | 5,184,035 | $5,862,000 | 2.30% |
Prescott General Partners LLC | 1,851,851 | $2,093,000 | 0.16% |
DAFNA Capital Management LLC | 140,000 | $158,000 | 0.04% |
Fort Sheridan Advisors LLC | 83,931 | $95,000 | 0.03% |
Long Focus Capital Management, LLC | 215,000 | $243,000 | 0.02% |
XTX Topco Ltd | 72,807 | $82,000 | 0.02% |
Ergoteles LLC | 490,895 | $555,000 | 0.02% |
Beirne Wealth Consulting Services, LLC | 45,000 | $51,000 | 0.02% |